Table 3.

Adjusted^a use of supportive care medications following diagnosis of BM by race (OR = odds ratio)

	White	African American OR [95% CI]	P	Hispanic OR [95% CI]	P	Asian OR [95% CI]	P
Pain medications
Non-opioid analgesics	Ref	0.89 [0.66–1.20]	0.44	0.69 [0.46–1.05]	0.08	0.97 [0.70–1.34]	0.86
Opioids	Ref	0.96 [0.85–1.08]	0.48	1.09 [0.94–1.26]	0.24	0.86 [0.75–0.99]	0.04
Medications for neurological symptoms
Anti-emetics	Ref	0.75 [0.68–0.83]	<0.001	0.91 [0.80–1.04]	0.16	0.83 [0.73–0.94]	0.004
Anti-epileptics	Ref	1.04 [0.92–1.18]	0.49	1.11 [0.95–1.29]	0.19	0.83 [0.71–0.97]	0.02
Headache aids	Ref	0.81 [0.73–0.90]	<0.001	0.83 [0.73–0.94]	0.004	0.81 [0.72–0.92]	0.001
Steroids	Ref	0.84 [0.76–0.93]	<0.001	0.90 [0.80–1.03]	0.12	0.81 [0.72–0.92]	0.001
Cognitive aids	Ref	0.78 [0.49–1.23]	0.28	1.17 [0.69–1.99]	0.56	1.04 [0.64–1.70]	0.88
Psychotropic medications
Antidepressants	Ref	0.68 [0.57–0.80]	<0.001	0.78 [0.64–0.97]	0.02	0.67 [0.53–0.85]	0.001
Anxiolytics	Ref	0.68 [0.56–0.82]	<0.001	0.63 [0.49–0.81]	<0.001	0.62 [0.48–0.80]	<0.001
Antidelirium/antipsychotic agentsb	Ref	1.21 [0.97–1.52]	0.09	0.57 [0.38–0.86]	0.008	1.23 [0.88–1.70]	0.22
Other
Muscle relaxants	Ref	0.92 [0.72–1.16]	0.48	0.85 [0.62–1.16]	0.30	0.60 [0.41–0.89]	0.01
Psychostimulantsb,c	Ref	0.14 [0.03–0.59]	0.007	0.15 [0.02–1.07]	0.06	0.93 [0.40–2.17]	0.87
Sleep aids	Ref	0.71 [0.61–0.83]	<0.001	0.78 [0.64–0.94]	0.01	1.00 [0.83–1.20]	0.98
Appetite stimulants	Ref	0.85 [0.77–0.94]	0.002	0.87 [0.76–0.99]	0.04	0.87 [0.76–0.99]	0.03

^aCovariates were adjusted for age, sex, marital status, ZIP code level high school completion rate and median household income, year of BM diagnosis, Charlson comorbidity index, and primary tumor site.

^b,cCovariates for use of prior medication (b) and melanoma as primary cancer site (c) were removed from select models due to nonconvergence.